CILP2

Across TCGA pan-cancer cohorts, CILP2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CILP2 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CILP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CILP2 expression acts as an unfavorable survival marker.

LSCC and PDAC are the cancer types where CILP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.547	0.903	.001	41	view →
PDAC	DFS	Tertile	III,IV	0.337	0.892	.026	11	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CILP2–LSCC (OS)

Open the LSCC breakdown →